Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Recruiting · NCT06679270 · Registry updated 2026-07-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, Skin Diseases, Metabolic, Skin and Connective Tissue Diseases, familial partial lipodystrophy, hereditary disease, laminopathy, lipodystrophy, metabolic disease, skin disorder | Recruiting | Phase 3 | 2026-07-16 | NCT06679270 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chiesi Farmaceutici S.p.A. | 24 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| Flourish Research | Boca Raton | United States | 3 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| The Medical College of Wisconsin | Milwaukee | United States | 17 |
| University of Alabama | Birmingham | United States | 25 |
| University of Michigan | Ann Arbour | United States | 1 |
| UT Southwestern Medical Center | Dallas | United States | 210 |